<DOC>
	<DOCNO>NCT01699776</DOCNO>
	<brief_summary>It establish serum concentration 0.5-0.9 ng/ml digoxin effective patient heart failure , especially presence atrial fibrillation ( AF ) . It claim ivabradine lower heart rate reduces symptoms improves clinical outcome patient heart failure . The effect ivabradine digoxin heart failure compare . Patients 22 patient ischemic heart failure , AF , diastolic dysfunction preserve leave ventricular systolic function treat digoxin ivabradine 3 month , accord randomization cross-over design . Collected data Medical history , physical examination , laboratory ( include proBNP serum digoxin concentration ) , ECG , 6-minute walk test , echocardiographic data ( LVEF , LAVi , e/e1 ratio ) .</brief_summary>
	<brief_title>Efficacy Study Digoxin &amp; Ivabradine Treat Heart Failure</brief_title>
	<detailed_description>Protocol This investigator-started study , cod GC &amp; PJ-dig-Iva 2009-2012 . The study plan accord Good Clinical Quality standard analysis perform use intention-to-treat method . The protocol approve Ethics Committee . Selected patient give write informed consent . The family practitioner agree obtain data analysis . Collected data analyze single-blinded investigator ( without knowledge use test drug time collection ) . Patients Study design : patient assign DIG IVA 3 month , accord randomization cross-over design . Tested drug Commercial brand digoxin ivabradine use . Digoxin give mouth dose 0.125 mg/day , 5 time per week , 3 month . Ivabradine give mouth dose 7.5 mg bid 3 month . Inclusion criterion Chronic stable coronary artery disease Permanent atrial fibrillation . Diastolic dysfunction maintain systolic function . Exclusion criterion Unstable angina pectoris . Reduced systolic cardiac function ( LVEF &lt; 52 % ) . Normal diastolic function . Diabetes require insulin . Moderate severe renal hepatic dysfunction . Technically insufficient echocardiographic quality . Collected data Medical history concomitant medication . Physical examination perform . Laboratory value ( include proBNP serum digoxin concentration ) . ECG . Echocardiography . 6-minute walk test . Statistical Analyses Data express mean ± 1 SD . Absolute value percent change relation baseline measurement analyze . The 2 hypothesis test : null hypothesis : mu1-mu2=0.0 , alternative hypothesis : mu1-mu2 &gt; &gt; 0.0 . Comparisons within group make use paired test non-parametric Wilcoxon signed-rank test , appropriate . Between-group comparison perform unpaired test non-parametric Mann-Whitney U test , respectively . Chi-square test Kruskal-Wallis test use compare continuous normally normally distribute qualitative variable , appropriate . Multivariate analysis variance perform . A p value &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>All patient heart failure NYHA ( New York Heart Association ) class III . All chronic stable coronary artery disease treat percutaneous dilatation stenting , and/or aortocoronary bypass . The pathology induce permanent AF heart failure leave ventricular diastolic dysfunction preserve systolic function . Preserved systolic function define LVEF ( leave ventricular ejection fraction ) ≥52 % . Left ventricular diastolic dysfunction define e/e1 ratio &gt; 15 ( septal spectral tissueDoppler ) . Unstable myocardial ischemia , reduce systolic cardiac function ( LVEF &lt; 52 % ) , diabetes mellitus require insulin , moderate severe renal hepatic dysfunction , technically insufficient echocardiography .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Digoxin</keyword>
	<keyword>Ivabradine</keyword>
	<keyword>atrial fibrillation .</keyword>
</DOC>